文献速递外周动脉疾病

经导管深静脉动脉化治疗无选择慢性肢体威胁性缺血的系统评价与荟萃分析

Evidence for transcatheter arterialization of deep veins in poor-option chronic limb-threatening ischemia: A systematic review and meta-analysis.
PubMed 文献 · J Vasc Surg · 2025-10-22

该系统评价与荟萃分析比较了经导管深静脉动脉化(TADV)与标准治疗在无选择慢性肢体威胁性缺血患者中的效果。TADV组12个月保肢率79.6%显著高于标准治疗组55.1%,无截肢生存率71.0%也显著优于37.3%,技术成功率97.6%。

要点

  • TADV组12个月保肢率79.6%,显著高于标准治疗组的55.1%(P < .001)。
  • TADV组无截肢生存率71.0%,显著优于标准治疗组的37.3%(P < .001)。
  • TADV技术成功率达97.6%(95%CI:93.8%,99.1%)。

核心结论

  • 在无选择慢性肢体威胁性缺血患者中,TADV相比标准治疗显示出显著更优的保肢率、无截肢生存率和伤口愈合。

研究设计与样本

  • 系统检索PubMed和Embase(2015-2025年)纳入4项TADV研究(n=197),与高风险慢性肢体威胁性缺血自然病史研究(n=180)的标准治疗队列进行比较。

主要发现

  • TADV组12个月保肢率为79.6%(95%CI:67.6%,93.9%),标准治疗组为55.1%,差异显著(P < .001)。
  • TADV组无截肢生存率为71.0%(95%CI:56.9%,88.6%),标准治疗组为37.3%,差异显著(P < .001)。
  • TADV研究的技术成功率为97.6%(95%CI:93.8%,99.1%)。

临床怎么用

  • 对于无常规血运重建选择的慢性肢体威胁性缺血患者,TADV可作为改善保肢和无截肢生存的治疗选择。

局限性

  • 比较对象为自然病史研究队列而非同期随机对照,可能存在混杂偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with chronic limb-threatening ischemia (CLTI) who are ineligible for conventional revascularization ("no-option") face a 1-year major amputation rate of up to 67%. Transcatheter arterialization of deep veins (TADV) has shown promising outcomes, but comparative data with standard-of-care (SoC) treatments are lacking. METHODS: This evidence summary reviews current data for the only Food and Drug Administration-approved, Conformité Européenne-marked TADV procedure vs SoC treatments. The TADV cohort consisted of studies of Food and Drug Administration-approved TADV procedures, yielded from a systematic search of PubMed and Embase (2015-2025) in no-option CLTI patients with Rutherford class 5 or 6 disease and inadequate conventional revascularization options. The SoC cohort consisted of the natural progression of high-risk chronic limb-threatening ischemia natural history study of 180 no-option CLTI patients treated with conventional strategies. RESULTS: Four TADV studies (n = 197) were compared with the natural progression of high-risk chronic limb-threatening ischemia registry (n = 180). The primary end point of limb salvage rates was significantly higher in the TADV cohort: 79.6% [95% confidence interval: 67.6%, 93.9%] vs 55.1% in the SoC cohort (P < .001) at 12 months. Amputation-free survival was superior in TADV patients: 71.0% [56.9%, 88.6%] vs 37.3% in SoC (P < .001). The technical success rate was 97.6% [93.8%, 99.1%] across TADV studies. CONCLUSIONS: TADV demonstrates substantially superior limb salvage, amputation-free survival, and wound healing compared with SoC in no-option CLTI patients, representing a transformative advancement for this challenging population.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Boya MN, Cieri IF, Rodriguez Alvarez AA, et al. Evidence for transcatheter arterialization of deep veins in poor-option chronic limb-threatening ischemia: A systematic review and meta-analysis. J Vasc Surg. 2025. PMID: 41135720. doi:10.1016/j.jvs.2025.08.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。